Intranasal administration of a stapled relaxin-3 mimetic has anxiolytic- and antidepressant-like activity in rats.
Subhi MarwariAnders PoulsenNorrapat ShihRajamani LakshminarayananR Manjunatha KiniCharles William JohannesBrian William DymockGavin Stewart DawePublished in: British journal of pharmacology (2019)
Our preclinical findings demonstrate that targeting the relaxin-3/RXFP3 receptor system via intranasal delivery of an i,i+7 stapled relaxin-3 mimetic may represent an effective treatment approach for depression, anxiety, and related neuropsychiatric disorders.